The dramatic approval of Lorcaserin, now known by the trade name Belviq, was announced on June 27, 2012. Lorcaserin, CAS# 846589-98-8, is the first drug to be approved for weight loss in over twelve years. This announcement, made by representatives from both Easai and Arena Pharmaceuticals was a welcome one for researchers, patients and practitioners[…]
Lorcaserin Approved as the First Weight Loss Drug in over a Decade
Anti-Obesity Product, Drug Research & Development API Tags: BMIlorcaserin Jul 02, 2012
Is Lorcaserin the Next Weight Loss Drug?
Anti-Obesity Product, Drug Research & Development API, NDA Tags: BMIlorcaserin Feb 21, 2012
Intended for weight management, including weight loss and maintenance of weight loss, lorcaserin is poised to become the next weight loss drug. Lorcaserin is aimed at clinically obese patients, or patients with a Body Mass Index, or BMI, >30, or patients who are overweight (BMI >27) and have at least one weight related co-morbid condition.[…]
LGM Pharma Supplies Ingredients for Several Anti-Obesity Drugs
Anti-Migraine, Anti-Obesity Product, Bulk Active Ingredient, Compounding API, Drug Research & Development API Tags: Drug AdministrationlorcaserinObesityTopiramate Aug 31, 2010
LGM Pharma supplies Topiramate, Bupropion, Naltrexone and Lorcaserin – Active Pharmaceutical Ingredients (APIs) used to treat obesity.